Purpose <p>We aimed to explore the value of [<sup>68</sup>Ga]Ga‑FAPI PET/CT for the evaluation of Langerhans cell histiocytosis (LCH) in comparison with [<sup>18</sup>F]FDG PET/CT.</p> Methods <p>Thirty-two patients pathologically diagnosed with LCH were enrolled in this study. [<sup>68</sup>Ga]Ga‑FAPI and [<sup>18</sup>F]FDG PET/CT were performed within 1 week to identify disease extent and status. The detectability and intensity of the involved organs were compared between these two tracers.</p> Results <p>Thirty patients had active disease while two had non-active disease. In patients with active disease, the most commonly involved organ was bone (27/30), and [<sup>68</sup>Ga]Ga-FAPI PET/CT detected more osseous lesions (106/106) than [<sup>18</sup>F]FDG PET/CT (52/106). [<sup>68</sup>Ga]Ga-FAPI also identified liver, skin, and salivary gland involvement, which were often missed by [<sup>18</sup>F]FDG. Although both tracers detected thymus and pituitary gland involvement, [<sup>68</sup>Ga]Ga-FAPI demonstrated higher image contrast and more diagnostic confidence. Lymph node involvement, however, was not visualized by [<sup>68</sup>Ga]Ga-FAPI. Due to the superior sensitivity of [<sup>68</sup>Ga]Ga-FAPI, approximately 30% (10/30) of patients experienced reclassification in disease status or subtype. Furthermore, [<sup>68</sup>Ga]Ga‑FAPI appeared to be advantageous in response assessment.</p> Conclusion <p>[<sup>68</sup>Ga]Ga-FAPI PET/CT outperforms [<sup>18</sup>F]FDG PET/CT in detecting osseous and extra-nodal lesions in LCH, providing a valuable tool for precise disease evaluation and treatment planning.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

[68Ga]Ga‑FAPI PET/CT in the evaluation of Langerhans cell histiocytosis: comparison with [18F]FDG PET/CT

  • Wenjie Zhang,
  • Yu Wu,
  • Linlin Guo,
  • Xin Li,
  • Guohua Shen

摘要

Purpose

We aimed to explore the value of [68Ga]Ga‑FAPI PET/CT for the evaluation of Langerhans cell histiocytosis (LCH) in comparison with [18F]FDG PET/CT.

Methods

Thirty-two patients pathologically diagnosed with LCH were enrolled in this study. [68Ga]Ga‑FAPI and [18F]FDG PET/CT were performed within 1 week to identify disease extent and status. The detectability and intensity of the involved organs were compared between these two tracers.

Results

Thirty patients had active disease while two had non-active disease. In patients with active disease, the most commonly involved organ was bone (27/30), and [68Ga]Ga-FAPI PET/CT detected more osseous lesions (106/106) than [18F]FDG PET/CT (52/106). [68Ga]Ga-FAPI also identified liver, skin, and salivary gland involvement, which were often missed by [18F]FDG. Although both tracers detected thymus and pituitary gland involvement, [68Ga]Ga-FAPI demonstrated higher image contrast and more diagnostic confidence. Lymph node involvement, however, was not visualized by [68Ga]Ga-FAPI. Due to the superior sensitivity of [68Ga]Ga-FAPI, approximately 30% (10/30) of patients experienced reclassification in disease status or subtype. Furthermore, [68Ga]Ga‑FAPI appeared to be advantageous in response assessment.

Conclusion

[68Ga]Ga-FAPI PET/CT outperforms [18F]FDG PET/CT in detecting osseous and extra-nodal lesions in LCH, providing a valuable tool for precise disease evaluation and treatment planning.